Shares of BioAtla, Inc. (BCAB) are trading 17% higher at a price of $9.37 at the time of this writing. While the company's share price is down very very far from it's high point this year, it's regaining ground today in a multi day upward move as investors continued to look beyond the company's dour Q3 results and get bullish about the possible profits from potential emergency use approvals for its COVID-19 treatment sabizabulin.

BioAtla, Inc. has been trading between a 52-week high of $43.24 and a 52-week low of $2.01. The stock has a market cap of $340 Million.

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.

BioAtla, Inc. (BCAB) CEO Jay Short on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha 08-13-22

Bioatla (BCAB) Investor Presentation - Slideshow
Seeking Alpha 08-12-22

US stock market closes higher, Dow Jones gains 1.63%
InstaForex 08-10-22

BioAtla Inc. (BCAB) Shares Are Down -91.48% So Far This Year
Marketing Sentinel 08-10-22

SWTX, ALLG and ISPO among mid-day movers
Seeking Alpha 08-10-22